Latest News and Press Releases

Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent potency to risankizumab with similar binding...

MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new...

ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human...

Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions Company on track to...

Paul Quinlan joins as General Counsel Alan Lada joins as VP of Investor Relations Kristine Ball, President & CEO of Antiva Biosciences, appointed to Board of Directors MENLO...

WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic...

Joe Senn, PhD, joins as SVP of Nonclinical Research & Development Rajiv Panwar, PhD, joins as VP and Head of Chemistry, Manufacturing, and Controls Appointments strengthen Oruka’s executive...

Dr. Goncalves, former CMO at Cara Therapeutics, joins Oruka as CMO Eugenia Levi, PharmD, former Head of Global Medical Affairs for Cosentyx at Novartis, also joins as VP, Medical Affairs ...

Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded...